BROADCASTS.com

Every week, The American Journal of Managed Care\xae\xa0(AJMC\xae) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.\n\nThis week, the top managed care news included a study demonstrating that diabetes drug canagliflozin cuts the risk of renal failure and death; the FDA approving the first targeted therapy for metastatic bladder cancer; approximately half of all cancer deaths are attributable to modifiable risk factors.\n\nRead more about the stories in this podcast:\nCREDENCE: Canagliflozin Cuts Risk of Renal Failure, Death 30% in Patients With Type 2 Diabetes, CKD: https://www.ajmc.com/newsroom/credence-canagliflozin-cuts-risk-of-renal-failure-death-30-in-patients-with-type-2-diabetes-ckd\nFDA Approves Erdafitinib, First Targeted Therapy for Metastatic Bladder Cancer: https://www.ajmc.com/newsroom/fda-approves-erdafitinib-first-targeted-therapy-for-metastatic-bladder-cancer\nNearly Half of Cancer Deaths Attributable to Modifiable Risk Factors: https://www.ajmc.com/newsroom/nearly-half-of-cancer-deaths-attributable-to-modifiable-risk-factors\nPanelists Offer an Insider Perspective of the Unstable Future of Genetic Testing Reimbursement: https://www.ajmc.com/conferences/flasco-2019/panelists-offer-an-insider-perspective-of-the-unstable-future-of-genetic-testing-reimbursement\nFLASCO Spring Session 2019: https://www.ajmc.com/conferences/flasco-2019\nDeaths Among Opioid Users: Impact of Potential Inappropriate Prescribing Practices: https://www.ajmc.com/journals/issue/2019/2019-vol25-n4/deaths-among-opioid-users-impact-of-potential-inappropriate-prescribing-practices\nThe American Journal of Managed Care\u2014April 2019: https://www.ajmc.com/journals/issue/2019/2019-vol25-n4